Estropipate

Estropipate, also known as piperazine estrone sulfate and sold under the brand names Harmogen, Improvera, Ogen, Ortho-Est, and Sulestrex among others, is an estrogen medication which is used mainly in menopausal hormone therapy in the treatment of menopausal symptoms. It is a salt of estrone sulfate and piperazine, and is transformed into estrone and estradiol in the body. It is taken by mouth.
Medical uses.
Estropipate is used to:
Available forms.
Estropipate is available in the form of 0.75, 1.5, 3, and 6 mg oral tablets.
Pharmacology.
Pharmacodynamics.
Estropipate is a prodrug of estrone and estradiol. Hence, it is an estrogen, or an agonist of the estrogen receptors.
Pharmacokinetics.
Estropipate is hydrolyzed into estrone in the body. Estrone can then be transformed into estradiol by 17β-hydroxysteroid dehydrogenase.
History.
Estropipate was introduced for medical use by Abbott in 1968. It was approved by the in the United States in 1991.
Society and culture.
Generic names.
"Estropipate" is the generic name of the drug and its , , and .
Brand names.
Estropipate is or has been marketed under the brand names Genoral, Harmogen, Improvera, Ogen, Ortho-Est, and Sulestrex among others.
Availability.
Estropipate appears to remain available only in the United States. In the past, estropipate has also been marketed in Canada, the United Kingdom, Ireland, Switzerland, Australia, South Africa, Mexico, and Indonesia.